Author(s)

Kouassi Kouamé Konan Yvon^*, Touré Moctar, Séka Evrard Narcisse, Oumou Kimso, Traoré Kadjatou, Odo Bitti Addé, Traoré Asmaho Danielle, Kagambega Arsène Gaëtan, Adoubi Innocent

Oncology Department of the Treichville University Hospital, Abidjan, Cote d’Ivoire.

Objective: Contribute to improving care for prostate cancer patients in Cote d’Ivoire by identifying the average time before the development of the hormone-resistance and inherent therapeutic strategies. Patients and Method: It was a retro and prospective study over three years performed at the University Teaching Hospital of Treichville in Abidjan. 84 patients with metastatic prostate adenocarcinoma and resistant to hormone therapy were involved in the study. The analysis of clinical records enabled us to integrate different parameters in our study. Results: Our patients were relatively young (an average age of 61 years) and most of them belonged to the middle socio-economic class (50%). The resistance occurred within an average period of 9 months. The mixing of Docetaxel and Prednisone chemotherapy was the most used method of treatment (70% of cases). However, few patients (9.5%) received Abiraterone Acetate. Digestive and hematologic toxicities were noticed but they could be controlled by inherent treatment or disappear spontaneously. After nine months of treatment, 54.24% of patients who received specific treatment were alive, but high rates of mortality were observed as for patients who were only treated symptomatically. Conclusion: The relatively short average time before the development of hormone-resistance shows the aggressiveness of prostate adenocarcinoma from black Africans. The main therapeutic standard in our context remains Taxane-based chemotherapy with a good and fair tolerance.

Cancer, Prostate, Occurrence Time, Resistance

Yvon, K. , Moctar, T. , Narcisse, S. , Kimso, O. , Kadjatou, T. , Addé, O. , Danielle, T. , Gaëtan, K. and Innocent, A. (2018) Metastatic (Advanced) Prostate Cancer Resistant to Castration: The Time before Resistance Development and Therapeutic Measures Undertaken in Cote d’Ivoire. Journal of Cancer Therapy, 9, 955-961. doi: 10.4236/jct.2019.912079.